Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Genetic Testing in Screening Patients with Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial

Multiple Cancer Types

This trial screens patients with colon or rectal cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) for genetic mutations for recommendation to a molecularly assigned therapy. Identifying gene mutations may help patients enroll onto target companion trials that target these mutations.
Colon, Rectal
N/A
Ciombor, Kristen
NCT03765736
VICCGI2011

Nashville Biosciences Blood Sample Collection Study

Multiple Cancer Types

Colon, Liver, Lung, Non Small Cell, Ovarian, Pancreatic, Rectal
N/A
Bernard, Gordon
VICCMD18123

COLON MAP: Colorectal Molecular Atlas Project

Colon

Colon
N/A
Shrubsole, Martha
VICCGI1905

Neratinib HER Mutation Basket Study

Multiple Cancer Types

This is an open-label, multicenter, multinational, Phase 2 basket study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in participants with HER (EGFR, HER2) mutation-positive solid tumors.
Bladder, Colon, Esophageal, Gastric/Gastroesophageal, Neuro-Oncology, Ovarian, Urologic, Uterine
II
Mayer, Ingrid
NCT01953926
VICCMD1403

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Multiple Cancer Types

This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body. In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
Colon, Rectal
II
Ciombor, Kristen
NCT03043313
VICCGI2035

A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Multiple Cancer Types

This is a three-part study of NUC-3373 administered by intravenous (IV) infusion across two administration schedules, in separate combinations with leucovorin (LV), oxaliplatin, oxaliplatin and VEGF pathway inhibitors, oxaliplatin and EGFR inbibitors, irinotecan, irinotecan and VEGF pathway inhibitors, and irinotecan and EGFR inhibitors. The primary objective is to identify a recommended dose for NUC-3373 when combined with these agents.
Colon, Phase I, Rectal
I
Ciombor, Kristen
NCT03428958
VICCGIP1851

A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer

Multiple Cancer Types

This is a global, randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial to compare the efficacy and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). Approximately 520 subjects will be randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC.
Colon, Rectal
III
Eng, Cathy
NCT04322539
VICCGI2045

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer

Multiple Cancer Types

An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer and metastatic breast cancer.
Colon, Miscellaneous, Phase I, Rectal
I
Eng, Cathy
NCT03251378
VICCGIP1965

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Multiple Cancer Types

This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth.
Colon, Rectal
II
Ciombor, Kristen
NCT04096417
VICCGI2028

Aspirin in Preventing Colorectal Cancer in Patients with Colorectal Adenoma

Multiple Cancer Types

This phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Colon, Rectal
II
Dai, Qi
NCT02965703
VICCGI17105

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: